CAR-T therapy for hard-to-control lupus
Treatments studied
Part of Immune system & allergy clinical trials.
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 70 years old
- Have severe lupus symptoms (a high lupus activity score) and meet lupus diagnosis rules
- Lupus must not respond well to at least two immunosuppressing medicines and/or one approved biologic for over 6 months
- Have certain blood counts in acceptable ranges (hemoglobin, white blood cells, neutrophils, and platelets)
- Have good heart function on an ultrasound test (ejection fraction at least 50%) and adequate kidney and liver function
- Be able to safely have cells collected from a vein (apheresis), with pregnancy prevention for women who can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
This trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells, to reset the immune system in people with severe autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome. It aims to reduce disease activity and potentially improve quality of life.
This trial tests a new immune cell therapy (CAR-T) for people with lupus that hasn't gotten better with standard treatments. The goal is to see if these modified cells can calm the overactive immune system and improve symptoms.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This trial tests a new type of cell therapy called CAR-T cells that target a protein called CD70 on immune cells. The goal is to see if it can help people with active lupus that has not improved with standard treatments.
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.